(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

Gilead’s Trodelvy fails in lung cancer and raises new questions on antibody drug conjugate drugs. By Matthew Herper Jan. 22, 2024. Reprints. Yichuan Cao/Sipa USA via AP Images.

Many Gilead Sciences investors have lost faith in Trodelvy in HR-positive, HER2-negative breast cancer after disappointing data on tumor progression. But the antibody-drug conjugate has now made a ...

Gilead Sciences said on Monday a late-stage trial of its antibody-drug conjugate Trodelvy failed to show that it significantly improved survival for previously treated patients with advanced non ...

Trodelvy has accelerated U.S. approval for treating advanced urothelial cancer, but Gilead on Thursday said a large trial failed to confirm that the drug improved survival.

Gilead Sciences' announced topline results from the Phase 3 TROPiCS-04 study on Trodelvy for metastatic urothelial cancer. The study did not meet the primary endpoint of overall survival but ...

Sept 7 (Reuters) - Gilead Sciences Inc's , opens new tab Trodelvy extended by 3.2 months the survival of patients with advanced stages of a common type of breast cancer, according to data released ...

Gilead Sciences' Trodelvy failed to improve survival for patients with advanced bladder cancer and only modestly extended the lives of previously treated patients with late-stage lung cancer in a ...

Gilead is conducting several other Trodelvy studies, including a trial of the drug as an initial treatment for triple-negative breast cancer patients who do not express PD-L1. Sponsored Bank Accounts ...